Scientia Advisors in the News
BioPharm Insight Quotes Jonathan Pan, Scientia Advisors, in articles on NPS' Gattex and KV Pharmaceutical's Makena
Jan-Feb-March 2011BioPharm Insight recently quoted Jonathan Pan in the following articles:
- NPS' Gattex may stumble on reimbursement hurdles, particularly in Europe - experts 2011-01-21: NPS Pharmaceuticals' (NASDAQ:NPSP) Gattex for short bowel syndrome (SBS) may face challenges with reimbursement and market uptake if the degree of clinical benefit is marginal, particularly in the EU, experts said.
- KV Pharmaceutical: Makena cost a hurdle for acceptance over current compounded option - physicians2011-02-28: KV Pharmaceutical (NYSE:KV.A) could face hurdles getting its recently FDA approved Makena (hydroxyprogesterone caproate) into the market with a price 200x more than its current compounded cost, experts said.
- KV Pharmaceutical's Makena unlikely to face threat from Watson's Prochieve, but pricing difference may swing some votes - experts 2011-03-02: KV Pharmaceuticals' (NYSE:KV.A) Makena is unlikely to have its sales impacted by the anticipated approval of Watson Pharmaceuticals (NYSE: WPI) and Columbia Laboratories' (NASDAQ: CBRX) Prochieve for the prevention of preterm birth, experts said.
SCIENTIA ADVISORS, LLC | info@scientiaadv.com
55 Cambridge Parkway, Suite 300E, Cambridge MA 02142 | Phone: 617-299-3000 | Fax: 617-812-0315
© 2012 Scientia Advisors LLC
